中山为什么大便有血块(中山华都肛肠医院几级怎么样) (今日更新中)

WASHINGTON, April 25 (Xinhua) -- A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.Working in cell lines from colorectal cancer patients, researchers found that the class of drugs called PARP inhibitors worked against tumors with mutations in the MRE11 gene.About 15 percent of all colorectal cancers have what's called microsatellite instability, a type of error in the DNA. About 82 percent of those tumors have the MRE11 gene mutation."This is a potential broader application for PARP inhibitors, beyond breast and ovarian cancer. This is a class of drug that's already shown safety in early clinical trials and now might benefit some colorectal cancer patients as well," says lead study author Eduardo Vilar-Sanchez, a hematology/oncology fellow at the university, in a statement.The study, which was published Monday in Cancer Research, also found that PARP inhibitors are even more effective when both copies of MRE11 were mutated. Each person carries two copies of each gene, which means mutations can occur in either one or both copies. The researchers suggest that PARP inhibitors could be targeted specifically to colorectal cancer patients who have two copies of the mutated gene.Researchers are planning a phase I clinical trial to look at using PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11. Future trials are being considered using PARP inhibitors to prevent colorectal cancer and other cancers in people with Lynch syndrome whose tumors have this mutation.Microsatellite instability is also seen in prostate cancer and endometrial cancer, suggesting potential for PARP inhibitors to play a role in additional types of cancer as well, Vilar-Sanchez says, adding that more research is needed in these areas.

SAN FRANCISCO, April 28 (Xinhua) -- Microsoft Corp. on Thursday posted quarterly revenue and earnings that both beat analysts' expectations.In its fiscal 2011 third quarter ended on March 31, the software giant reported revenue of 16.43 billion U.S. dollars, up 13 percent from the same period a year earlier.Net income and earnings per share were 5.23 billion dollars and 61 cents, representing increases of 31 percent and 36 percent respectively year-on-year.Analysts had expected earnings of 56 cents per share on revenue of 16.19 billion dollars, according to Thomson Reuters."We delivered strong financial results despite a mixed PC environment, which demonstrates the strength and breadth of our businesses," Peter Klein, chief financial officer at Microsoft, said in a statement."Consumers are purchasing Office 2010, Xbox and Kinect at tremendous rates, and businesses of all sizes are purchasing Microsoft platforms and applications," he added.Revenue at four of Microsoft's five major divisions posted double-digit growth in the quarter, indicating the increase of technology spending by enterprises as well as strong demand for the company's entertainment products.The entertainment and devices division saw the biggest revenue growth of 60 percent, which according to Microsoft, were driven by strong demand for its Kinect hands-free motion control system for Xbox 360 and continued strong sales of Xbox 360 console.However, revenue for the division of the company's flagship Windows operating system dropped 4 percent in the quarter, which Microsoft said was "in line with the PC trends."The performance of the Windows division may fuel new concerns that Microsoft's dominance in software for PCs is being threatened by Apple's iPad and tablet computers running other operating systems, some analysts noted.

WASHINGTON, April 13 (Xinhua) -- The U.S. Food and Drug Administration (FDA) announced on Wednesday that it has approved the cPAX Aneurysm Treatment System for surgery on brain aneurysms that are difficult to manage because of their size and shape.An aneurysm is a bulge in the wall of a blood vessel, which can rupture as it increases in size, causing hemorrhage or death. Brain aneurysms often produce no symptoms until they grow and press on nerves in the brain, or until they begin to leak blood or rupture.Aneurysms can be repaired in two ways: surgeons can close the base of the aneurysm with a surgical clip, or use a technique commonly known as coiling, in which surgeons use a catheter to thread metallic coils through a blood vessel in the groin and into the blood vessel in the brain that contains the aneurysm. Surgeons then fill the aneurysm with the detachable coils, which block it from circulation and cause blood to clot, effectively destroying the aneurysm.Aneurysms larger than 10 millimeters are difficult to treat with clipping or coiling. The cPAX device system is indicated for use in those brain aneurysms."Like coiling, the cPAX Aneurysm Treatment System is a form of endovascular repair," said Christy Foreman, director of the Office of Device Evaluation in the FDA's Center for Devices and Radiological Health. "But instead of tiny metallic coils, it uses a special polymer material to fill the space within the aneurysm."According to the FDA, the cPAX device system is indicated for use in adults aged 22 and older and should not be used in patients with an active infection or in those in whom anticoagulation and antiplatelet therapy is contraindicated.

BEIJING, Feb. 12 (Xinhua) -- China's recent revocation of a national scientific award due to academic fraud has been welcomed by the public, but experts warn the country still has a long way to go to bring an end to such dubious academic practices.On Feb. 1, China's Ministry of Science and Technology, revoked the State Scientific and Technological Progress Award (SSTPA) given to Li Liansheng, former professor of Xi'an Jiaotong University in 2005.An investigation found Li had plagiarized others' works and fabricated data in his winning project, a research on key technologies for designing and manufacturing scroll compressors. Li was investigated after the science ministry received tip-offs from six professors (including four retired) in his university.The ministry subsequently canceled his prize and retrieved the money awarded.Zhao Baojing, a senior official with the National Office for S&T Award, told Xinhua it was the first time China had withdrawn a national scientific honor.The revocation soon sparked pubic discussion over academic integrity. Tan Gang, a citizen in Shenzhen, wrote on his microblog, "Though the revocation came a bit late, it is progress. It's a warning against academic misconduct."Shi Ying, vice director of Shanxi Academy of Social Sciences, said, the move demonstrated China's "zero-tolerance" for academic fraud, and would help clean up the academic field."However, academic fraud is still rampant, which not only damages academic integrity, but also harms the innovative capacity of China in a broader sense," said Shi.Anti-fraud activist Fang Zhouzi, who runs a website on anti-academic fraud from his Beijing home, said "This is by far the harshest stance China has ever taken against academic fraud, which should be viewed as progress." He so noted China still has a long way to go in the fight against academic fraud.Fang said, the science ministry's move does not mean China is really cracking down on academic fraud. The plagiarist might have not been found out if it were not for years of unyielding efforts made by the six professors.The scandal again highlights that academic fraud is alive and well in China. A survey conducted among 30,078 respondents in 2009 by the China Association for Science and Technology (CAST) showed that nearly half of the science-related workers in China's research institutes, universities, medical institutes and hospitals think academic cheating is "common."Fang attributed the prevalence of academic fraud in China to lax punishments and loopholes in the academic evaluation system.Zero tolerance of academic fraudChina's science minister, Wan Gang, said on several occasions "We hold zero tolerance for academic fraud."However, Fang said "zero tolerance" was a slogan rather than the actual case. Many cases of academic fraud, even publicly exposed, were "tolerated" eventually. "Lax punishment makes academic fraud less costly."

来源：资阳报